• MK-571 (L-660,711) leukotriene D4 receptor antagonist: Pract

  2026-08-01

  This article translates laboratory pain points into scenario-driven solutions using MK-571 (L-660,711) leukotriene D4 receptor antagonist (SKU B7023). Emphasizing validated protocols, reproducibility, and mechanistic clarity, it demonstrates how APExBIO’s MK-571 empowers biomedical researchers to dissect leukotriene-mediated inflammation, bronchoconstriction, and multidrug resistance with confidence.

• Propranolol in Research: Workflows for Cardiovascular & Memo

  2026-07-31

  Propranolol, a non-selective β-adrenergic receptor blocker, empowers researchers to bridge cardiovascular, metabolic, and neurobehavioral domains with reproducible workflows. This guide delivers actionable protocol enhancements, troubleshooting insights, and a translational outlook on leveraging Propranolol for emotional memory modulation and essential tremor therapy.

• Carvedilol Phosphate in IRI Models: Protocols and Innovation

  2026-07-31

  Carvedilol Phosphate, a high-purity non-selective beta blocker, is redefining cardiovascular and hepatic ischemia–reperfusion injury research. This guide translates the latest mechanistic breakthroughs into actionable protocols and troubleshooting insights, empowering researchers to model beta-adrenergic signaling and macrophage polarization with confidence.

• TCAIM Regulates Mitochondrial Metabolism via OGDH Control

  2026-07-30

  Wang et al. identify the mitochondrial co-chaperone TCAIM as a specific regulator of the a-ketoglutarate dehydrogenase (OGDH) protein, revealing a novel post-translational mechanism that modulates central metabolic flux. Their findings demonstrate how targeted degradation of OGDH by TCAIM, mediated by mitochondrial HSPA9 and LONP1, impacts TCA cycle activity and cellular energy balance—insights that may inform future metabolic engineering and disease modeling.

• Phillygenin Modulates Inflammation in Diabetic Nephropathy M

  2026-07-30

  A recent study demonstrates that phillygenin mitigates diabetic nephropathy by suppressing pro-inflammatory and apoptotic signaling through targeted modulation of TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β pathways. This work establishes a molecular rationale for phillygenin as a candidate therapy in renal disease models.

• Elucidating TET2 Regulation: Protocols for Metabolite Bindin

  2026-07-29

  Zhang et al. present a detailed protocol combining biochemical assays and saturation transfer difference (STD) NMR spectroscopy to experimentally validate metabolite binding and regulatory effects on TET2 dioxygenase. This approach offers a robust framework for investigating how cellular metabolism directly modulates epigenetic enzyme activity, with implications for understanding tumorigenesis and therapeutic intervention.

• V5 Epitope Tag Peptide: Enhanced Protein Tagging Workflows

  2026-07-29

  The V5 Epitope Tag Peptide (GKPIPNPLLGLDST) empowers reproducible, multiplexed detection and streamlined purification of recombinant proteins, even in complex imaging and immunodetection assays. APExBIO's ultra-pure synthetic peptide supports advanced protocol optimization, addressing emerging challenges in super-resolution applications and antibody screening.

• Geneticin, G-418 Sulfate: Decoding Selective Pressure & Anti

  2026-07-28

  Explore how Geneticin (G-418 Sulfate) advances genetic engineering selection and antiviral research, with new insights into ribosomal inhibition and implications for cell plasticity. This article dissects mechanisms, protocol nuances, and the translational impact of this versatile compound.

• nPEC Enables Accurate Dual-Loaded Liposome Encapsulation Ana

  2026-07-28

  This study establishes nanoparticle exclusion chromatography (nPEC) as a universally applicable and accurate method for determining encapsulation efficiency in dual-loaded liposomes containing both hydrophilic and lipophilic drugs. The findings address a major analytical challenge in combinatorial drug delivery, enabling improved reliability and broader applicability for advanced nanocarrier systems.

• Induction of Right Ventricular Cardiomyocytes from hPSCs

  2026-07-27

  Saito et al. present a robust method to generate right ventricular-like cardiomyocytes from human pluripotent stem cells by modulating BMP signaling during mesoderm induction. This chamber-specific differentiation approach enables more accurate disease modeling and therapeutic research for right ventricular cardiac disorders.

• Honokiol and Immunometabolism: Next-Gen Insights for Cancer

  2026-07-27

  Explore how Honokiol, a potent antioxidant and NF-κB pathway inhibitor, intersects with emerging immunometabolic science to advance cancer research. This article offers a unique mechanistic perspective and practical guidance beyond conventional workflow discussions.

• Nonconventional Agonist-Antagonist Dynamics at the GLP-1 Rec

  2026-07-26

  This article examines the innovation and findings of Chepurny et al.'s high-throughput FRET study, which reveals previously unrecognized cross-reactivity between glucagon and GLP-1 receptor ligands. Their results challenge the traditional view of receptor selectivity and have important implications for the design and interpretation of metabolic and diabetes research.

• CLCC1 Identified as a Key Host Factor in Herpesvirus Nuclear

  2026-07-25

  This study uncovers the essential role of the chloride channel CLCC1 in mediating membrane fusion during the nuclear egress of herpesviruses. Using a genome-scale CRISPR screen, the authors provide mechanistic insight into a previously unresolved step in herpesvirus maturation, with implications for understanding host-virus interactions and potential antiviral targets.

• SGI-1027: Mechanistic Insights and Protocols for DNMT1-Targe

  2026-07-24

  Discover the advanced mechanisms and assay protocols of SGI-1027, a leading DNA methyltransferase inhibitor, with in-depth analysis of its impact on tumor suppressor gene reactivation and cancer research applications.

• Eltanexor (KPT-8602): Optimizing Cancer Research Workflows

  2026-07-24

  Eltanexor (KPT-8602) is redefining translational cancer research by targeting nuclear export with high selectivity and a superior safety profile. This article provides actionable protocols, advanced use-cases, and troubleshooting strategies to unlock its full experimental potential in both hematological and solid tumor models.

547 records 9/37 page Previous Next First page 上5页 678910 下5页 Last page